cagrisema semaglutide cagrilintide phase 3 results 2024 2025 obesity Cagrilintide–semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, study CAGRISEMA: The Latest Breakthrough in
CAGRISEMA: The Latest Breakthrough in Weight Loss Medication A stronger Ozempic is coming. What to know about CagriSema, Novo Nordisk's new weight loss drug CagrilintideSemaglutide in Adults with Overweight or Obesity and Type 2 Diabetes New England Journal of Medicine Novo Nordisk's CagriSema outperforms Ozempic in Phase III trial Novo Nordisk's CagriSema 2.4 mg 2.4 mg demonstrated significant reduction in HbA1c and weight across multiple studies in the REIMAGINE program presented at ADA 2026
Pay in 4 interest-free payments of $6.05 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13




